Daily Anesthesiology Research Analysis
Analyzed 41 papers and selected 3 impactful papers.
Summary
The most impactful papers identify clinically actionable advances in pediatric anesthetic safety, demonstrate a novel peptide-based depot for prolonged local anesthesia, and provide a rigorously controlled negative trial showing that 24-hour lidocaine infusion does not prevent chronic postthoracotomy pain. Together, these studies illustrate the value of dose-finding trials, translational biomaterials research, and well-designed negative evidence for refining anesthetic practice.
Research Themes
- Pediatric anesthetic safety and dose optimization
- Translational drug-delivery systems for prolonged regional anesthesia
- Negative evidence and prevention of chronic postsurgical pain
Selected Articles
1. Median effective dose of intravenous nalmefene for preventing sufentanil-induced cough in children aged 1-6 years: a prospective randomized controlled trial.
This prospective, randomized, double-blind, placebo-controlled trial included 249 children aged 1–6 years and evaluated nalmefene doses before sufentanil administration. Sufentanil-induced cough declined dose-dependently, from 45.9% with saline to 11.3% with nalmefene 0.1 μg/kg, with an estimated ED50 of 0.064 μg/kg and preserved hemodynamic stability and postoperative analgesia.
Impact: The study supplies a prospectively registered, age-specific dose reference for preventing a potentially hazardous opioid-related airway response in young children. Its dose-response design directly supports translation into pediatric anesthesia protocols.
Clinical Implications: Nalmefene around the estimated ED50 may be considered as a prophylactic strategy for sufentanil-induced cough in children aged 1–6 years, while monitoring for opioid-antagonist effects and confirming efficacy in broader surgical populations.
Key Findings
- The trial enrolled 249 children aged 1–6 years and was prospectively registered under ChiCTR2500111207.
- Sufentanil-induced cough decreased from 45.9% with saline to 11.3% with nalmefene 0.1 μg/kg.
- The estimated nalmefene ED50 was 0.064 μg/kg, with preserved hemodynamic stability and postoperative analgesia.
Methodological Strengths
- Prospective randomized, double-blind, placebo-controlled, four-arm dose-ranging design.
- Use of a sigmoidal Emax model with bootstrap confidence intervals to estimate ED50.
Limitations
- The study evaluated elective laparoscopic surgery and may not generalize to emergency surgery or other pediatric procedures.
- The abstract provides limited information on adverse events beyond hemodynamic stability and postoperative analgesia.
Future Directions: Future multicenter trials should confirm the dose across different ages, surgical settings, opioid regimens, and respiratory-risk groups, while systematically evaluating analgesia, withdrawal-related effects, and rare adverse events.
BACKGROUND: Sufentanil-induced cough (SIC) during anesthetic induction carries greater risks in young children than in adults owing to their limited functional residual capacity and elevated oxygen demand. No optimal prophylactic dose of intravenous nalmefene has been established for this age group. We aimed to determine the median effective dose (ED50) of nalmefene for preventing SIC in children aged 1-6 years. METHODS: In this prospective, randomized, double-blind, placebo-controlled trial (ChiCTR2500111207), 249 children aged 1-6 years undergoing elective laparoscopic surgery were assigned 1:1:1:1 to normal saline (Group A) or nalmefene 0.025, 0.05, or 0.1 μg/kg (Groups B, C, and D), each administered one minute before sufentanil 0.2 μg/kg.
2. Peptide Coacervates as Dynamic and Interactive Depots for Tetrodotoxin in Long-Acting Local Anesthesia.
This mechanistic and translational study developed a mussel foot protein-inspired peptide coacervate that binds tetrodotoxin through multivalent noncovalent interactions and enables sustained release. In rats, the formulation prolonged sensory nerve blockade to 10.5 hours and reduced systemic toxicity 1.5-fold compared with tetrodotoxin alone, while molecular simulations supported the proposed hydrogen-bonding mechanism.
Impact: The work addresses a central limitation of long-acting local anesthesia: delivering highly water-soluble molecules without sacrificing potency or safety. It combines materials engineering, molecular mechanism, and in vivo regional anesthesia in a platform with potential applicability beyond tetrodotoxin.
Clinical Implications: The platform could eventually support longer-lasting single-injection nerve blocks and reduce systemic toxicity, but clinical use requires extensive toxicology, reproducibility, dose optimization, and human safety testing.
Key Findings
- Mfp3s-pep spontaneously formed coacervates under physiological conditions and sequestered 29% of tetrodotoxin.
- The tetrodotoxin–Mfp3s-pep formulation prolonged sensory blockade in a rat sciatic nerve model to 10.5 hours.
- The formulation reduced systemic toxicity 1.5-fold compared with tetrodotoxin alone, with molecular modeling supporting dynamic hydrogen-bonding interactions.
Methodological Strengths
- Integrated physicochemical characterization, molecular docking, molecular dynamics, and in vivo nerve-block testing.
- Demonstrated both prolonged pharmacologic effect and reduced systemic toxicity in an animal model.
Limitations
- The evidence is preclinical and was generated in a rat sciatic nerve block model.
- Long-term neurotoxicity, immunogenicity, pharmacokinetics, manufacturing scalability, and human safety were not established.
Future Directions: Future studies should define dose–response relationships, tissue distribution, duration of sensory and motor block, repeat-dose safety, neurotoxicity, and efficacy in larger animal models before considering first-in-human studies.
Hydrophilic small-molecule therapeutics are difficult to encapsulate using conventional depot delivery systems because of their high-water solubility and rapid diffusion. Here we report a drug-interactive peptide coacervate platform for sustained release of tetrodotoxin (TTX), a potent site-1 sodium channel blocker used for local anesthesia. We discovered that a mussel foot protein-inspired peptide (Mfp3s-pep) interacts with TTX and undergoes spontaneous self-coacervation under physiological conditions, forming dynamic assemblies that encapsulate TTX via multivalent noncovalent interactions. The Mfp3s-pep coacervates sequester 29% of TTX and significantly prolong its release. In a rat sciatic nerve block model, the TTX-Mfp3s-pep formulation extended sensory blockade up to 10.5 h and reduced systemic toxicity by 1.5-fold, which had not been achievable with TTX alone without drug synergy.
3. Perioperative 24-Hour Lidocaine Infusion Does Not Prevent Chronic Postthoracotomy Pain: A Triple-Blinded Randomized Controlled Trial.
In this triple-blinded randomized trial of 71 patients undergoing video-assisted thoracoscopic surgery, 24-hour perioperative lidocaine infusion did not reduce chronic postsurgical pain at 3 or 6 months. It also failed to improve acute pain or opioid consumption and increased dizziness, providing clinically important evidence against extending lidocaine infusion for this preventive purpose.
Impact: The study directly tests a plausible strategy intended to overcome prior concerns about inadequate lidocaine exposure and finds no benefit. This negative result can prevent ineffective treatment, reduce medication-related harm, and redirect research toward better-supported preventive interventions.
Clinical Implications: Routine 24-hour perioperative lidocaine infusion should not be adopted solely to prevent chronic postthoracotomy pain in patients receiving multimodal analgesia. Clinicians should weigh the lack of demonstrated benefit against increased dizziness.
Key Findings
- Chronic postsurgical pain at 3 months occurred in 50% of both the lidocaine and placebo groups.
- At 6 months, pain incidence remained statistically similar: 27% with placebo versus 32% with lidocaine.
- Lidocaine increased dizziness during infusion, occurring in 47% versus 14% with placebo, without reducing acute pain or opioid use.
Methodological Strengths
- Triple-blinded, randomized, placebo-controlled design with a clinically relevant chronic pain endpoint.
- Assessment of both short-term outcomes and chronic pain through 6 months.
Limitations
- The sample size was small, with 71 participants, limiting precision and detection of modest treatment effects.
- Follow-up was limited to 6 months and the study was conducted at a single tertiary center.
Future Directions: Future research should identify patient subgroups or surgical techniques that may benefit from systemic lidocaine and compare other chronic postsurgical pain prevention strategies using adequately powered, multicenter trials with longer follow-up.
BACKGROUND: Managing chronic postsurgical pain is challenging. Evidence supporting the use of perioperative lidocaine to prevent it is inconsistent, potentially due to insufficient infusion duration. OBJECTIVES: To determine the effect of extending lidocaine infusion to 24 hours for treating chronic postsurgical pain in patients undergoing video-assisted thoracoscopic surgery. STUDY DESIGN: Triple-blind, controlled randomized trial. SETTING: A tertiary center in a university hospital. METHODS: Seventy-one patients undergoing elective video-assisted thoracoscopic surgery were randomized 1:1 to receive either 2% lidocaine or placebo infusion at a speed of 4 mL/h started after anesthesia induction and continued for 24 hours. Primary outcomes were chronic postsurgical pain at 3 months defined as present pain score > 0 on an 11-point Numeric Rating Scale. Secondary outcomes included acute pain and opioid use during the first postsurgical 48 hours, and chronic postsurgical pain for up to 6 months.